All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The ins and outs of CAR T cells in the real world: Live Hub event
During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite session on the ins and outs of CAR T-cells in the real world.
Here the Multiple Myeloma Hub is pleased to share the presentation by Shaji Kumar, Mayo Clinic, Rochester, US, on biomarkers and eligibility for CAR T-cell therapies in multiple myeloma.
In this presentation, Shaji Kumar shares the currently approved CAR T-cell products for MM, discussing their up-to-date clinical data (Figure 1). He also shares the limitations and logistical challenges facing the implementation CAR T-cell therapy, as well as the current eligibility criteria for its use (Figure 2).
Figure 1. Efficacy and safety data for KarMMa and CARITITUDE-1*
AE, adverse event; CR, complete response; CRS, cytokine release syndrome; DoR, duration of response; ICANS, mmune effector cell-associated neurotoxicity syndrome; MRD, minimal residual disease; NR, not reached; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; OS, overall survival; VGPR, very good partial response.
*Adapted Chekol Abebe, et al.,1 Martin T, et al.,2 and Munshi, et al.3
Figure 2. Eligibility criteria for the use of CAR T-cell products*
CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group Performance Status; SCT, stem cell transplant.
*Adapted from Dave, et al.4
Watch or download the presentation to learn more about:
This activity was supported through an educational grant from Bristol Myers Squibb.
The ins and outs of CAR T cells in the real world: Live Hub event
Subscribe to get the best content related to multiple myeloma delivered to your inbox